p53 IHC for Barrett's HGD / dysplasia (aberrant expression)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-P53-IHC-DYSPLASIA |
|---|---|
| Type | Biomarker |
| Aliases | TP53 IHC Barrett'saberrant p53 in dysplasiap53 IHC in Barrett's high-grade dysplasiap53 surveillance IHCp53 ІГХ при дисплазії Барретта (аберантна експресія) |
| Status | reviewed 2026-05-18 |
| Diseases | None declared |
| Sources | SRC-NCCN-ESOPHAGEAL-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Measurement | MethodIHC on FFPE biopsy (DO-7 or BP53-12 clone); aberrant = diffuse strong (>80%, 3+) OR null (0% with internal control intact) Unitscategorical: aberrant (overexpression OR null) | wild-type pattern |
| Related biomarkers | BIO-TP53-IHC BIO-TP53-MUTATION |
Notes
STUB. BSG/AGA-endorsed adjunct in Barrett's surveillance: aberrant p53 IHC upgrades indefinite-for-dysplasia or low-grade dysplasia toward high-grade behavior, shortening surveillance interval and triggering endoscopic eradication therapy (RFA / EMR). Distinct from BIO-TP53-IHC (endometrial/HGSOC treatment-stratification scope) — this entry is the Barrett's-specific surveillance application.
Used By
No reverse references found in the YAML corpus.